New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Blood

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V86.3.855.855PMID 7620181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

  1995cited by this paper
• Treatment of primary amyloidosis.

  1995cited by this paper
• Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.

  1995cited by this paper
• The treatment of multiple myeloma.

  1994cited by this paper
• High-dose therapy and autologous transplantation in amyloidosis-AL.

  1993cited by this paper
• Use of an Anti‐Idiotypic Monoclonal Antibody in Studying Amyloidogenic Light Chains in Cells, Urine and Fibrils: Pathophysiology and Clinical Implications

  1992cited by this paper
• Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

  1992cited by this paper
• Delta-positive T-cell lymphoma that produces interferon gamma.

  1992cited by this paper
• Response rates and survival in primary systemic amyloidosis.

  1991cited by this paper
• Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

  1990cited by this paper
• Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.

  1990cited by this paper
• Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity

  1990cited by this paper
• Systemic amyloidosis.

  1990cited by this paper
• Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973).

  1987cited by this paper
• Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.

  1987cited by this paper
• Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.

  1986cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• THE VALUE AND LIMITATIONS OF THE CONGO RED TEST FOR AMYLOIDOSIS

  1944cited by this paper

• Small-Molecule Inhibitors of Amyloid Beta: Insights from Molecular Dynamics—Part A: Endogenous Compounds and Repurposed Drugs

  2025cites this paper
• Doxycycline: An essential tool for Alzheimer’s disease

  2025cites this paper
• Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective

  2024cites this paper
• Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.

  2024cites this paper
• Birtamimab: a new amyloidosis treatment?

  2023cites this paper
• Amyloid Disassembly: What Can We Learn from Chaperones?

  2022cites this paper
• Changes in Brain Functional and Effective Connectivity After Treatment for Breast Cancer and Implications for Intervention Targets

  2021cites this paper
• Conventional Therapy for Amyloid Light-Chain Amyloidosis

  2020cites this paper
• Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis

  2020cites this paper
• The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with Aβ42

  2019cites this paper
• Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms

  2018influential citation
• AL amyloidosis: advances in diagnostics and treatment.

  2018cites this paper
• AL amyloidosis: from molecular mechanisms to targeted therapies.

  2017cites this paper
• Translational Research in Alzheimer’s and Prion Diseases

  2017cites this paper
• Kidney Involvement in Light Chain Amyloidosis

  2017cites this paper
• New and developing therapies for AL amyloidosis

  2017cites this paper
• What is new in diagnosis and management of light chain amyloidosis?

  2016cites this paper
• Systemic amyloidosis: novel therapies and role of biomarkers.

  2016cites this paper
• Emerging treatments for amyloidosis.

  2015cites this paper
• Novel strategies for the diagnosis and treatment of cardiac amyloidosis

  2015cites this paper
• Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure

  2015cites this paper
• An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis

  2014cites this paper
• A new face for old antibiotics: tetracyclines in treatment of amyloidoses.

  2013cites this paper
• Systemic amyloidoses: what an internist should know.

  2013cites this paper
• Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis

  2012cites this paper
• Primary amyloidosis treated with continuous ambulatory peritoneal dialysis.

  2012cites this paper
• Mutations Associated with Amyloidosis Mutation Codon Clinical Geographical Mutation Codon Clinical Geographical Change Features

  2012cites this paper
• Transthyretin-associated Familial Amyloid Polyneuropathy – Current and Emerging Therapies

  2012cites this paper
• Transthyretin-associated Familial Amyloid Polyneuropathy — Current and Emerging Therapies

  2012cites this paper
• Toward Personalized Medicine: The potential role of RNA interference in Plasma Cell Dyscrasia

  2011cites this paper
• Amyloid heart disease.

  2010cites this paper
• Rôle des cellules immunitaires et effets des cannabinoïdes dans la physiopathologie des maladies à prions

  2008cites this paper
• Klinik und Therapie der AL-Amyloidose

  2008cites this paper
• Localized Amyloidosis and Alzheimer's Disease: The Rationale for Weekly Long-Term Low Dose Amyloid-Based Fractionated Radiotherapy

  2008cites this paper
• AL Amyloidosis with Renal Involvement

  2007cites this paper
• Altered Biogenesis of ΔF508-CFTR Following Treatment with Doxorubicin

  2007cites this paper
• Lambda II immunoglobulin light chain protein in primary localized rectal amyloidosis

  2007cites this paper
• Identification de cibles intracellulaires de molécules à activité antiprion

  2007influential citation
• Altered biogenesis of deltaF508-CFTR following treatment with doxorubicin.

  2007cites this paper
• An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

  2007cites this paper
• Ability of carbazole salts, inhibitors of Alzheimer beta-amyloid fibril formation, to cross cellular membranes.

  2007cites this paper
• Paraproteinemic neuropathy.

  2007cites this paper
• A systematic review of prion therapeutics in experimental models.

  2006cites this paper
• Prion Diseases

  2006cites this paper
• An intriguing case of primary amyloidosis with cardiac involvement: symptomatic and echocardiographic improvement with thalidomide treatment.

  2006cites this paper
• Light-chain (AL) amyloidosis: diagnosis and treatment.

  2006cites this paper
• Myeloma--new approaches to combined nephrological-haematological management.

  2006cites this paper
• Amyloidosis

  2006cites this paper
• Resolution of primary amyloidosis by melphalan and prednisolone: a case report.

  2005cites this paper
• Current therapeutic strategies in cardiac amyloidosis

  2005cites this paper
• Clinical aspects of systemic amyloid diseases.

  2005cites this paper
• Emerging treatment approaches for the systemic amyloidoses.

  2005cites this paper
• Cardiac amyloidosis.

  2005cites this paper
• Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease".

  2004cites this paper
• Fine‐needle aspiration of abdominal fat pad for amyloid detection: A clinically useful test?

  2004cites this paper
• High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

  2004cites this paper
• Therapeutic options in systemic AL amyloidosis.

  2004cites this paper
• Towards understanding the structure-function relationship of human amyloid disease.

  2004cites this paper
• [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].

  2004cites this paper
• Therapy for immunoglobulin light chain amyloidosis: the new and the old.

  2004cites this paper
• High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial

  2004cites this paper
• [Primary amyloidosis associated to severe factor X deficiency].

  2004cites this paper
• The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

  2004cites this paper
• Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.

  2003cites this paper
• Molecular mechanisms of amyloidosis.

  2003cites this paper
• Régulation concertée de l'expression des chaînes d'immunoglobulines et conséquences de ses anomalies en pathologie

  2003cites this paper
• Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid-Reactive Monoclonal Antibodies

  2003cites this paper
• Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.

  2003cites this paper
• 4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters

  2003cites this paper
• Therapeutic approaches to prion diseases.

  2003cites this paper
• Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

  2003cites this paper
• Interaction studies of the cellular prion protein

  2002cites this paper
• Immunoglobulin light chain amyloidosis and the kidney.

  2002cites this paper
• A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

  2002cites this paper
• Characterization of the 37-kDa/67-kDa laminin receptor as the cell surface receptor for the cellular prion protein

  2002cites this paper
• Primary systemic amyloidosis

  2002cites this paper
• Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro.

  2002cites this paper
• Kidney and liver involvement in monoclonal light chain disorders.

  2002cites this paper
• Biological features of the clone involved in primary amyloidosis (AL)

  2001cites this paper
• Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.

  2001cites this paper
• Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens.

  2001cites this paper
• Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules.

  2001cites this paper
• Prospects for effective treatment of AL amyloidosis?

  2000cites this paper
• [Treatments for amyloidosis beyond symptomatic care].

  2000cites this paper
• Novel approaches to the treatment of primary amyloidosis

  2000cites this paper
• Therapieoptionen bei systemischer AL-Amyloidose mit Nierenbeteiligung

  2000cites this paper
• Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.

  2000cites this paper
• Diagnosis and treatment of AL amyloidosis.

  2000cites this paper
• [Therapy options in systemic AL-amyloidosis with renal involvement].

  2000cites this paper
• A domestic fight or something else?

  2000cites this paper
• Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.

  2000cites this paper
• New therapeutic approaches in primary systemic AL amyloidosis

  2000cites this paper
• 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.

  2000cites this paper
• The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.

  2000cites this paper
• Usefulness of serum hepatocyte growth factor for the diagnosis of amyloidosis.

  2000cites this paper
• Antibody-mediated resolution of light chain-associated amyloid deposits.

  2000cites this paper
• Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin.

  1999cites this paper
• Current Drug Therapy for Multiple Myeloma

  1999cites this paper
• Computationally derived structural models of the beta-amyloid found in Alzheimer's disease plaques and the interaction with possible aggregation inhibitors.

  1999cites this paper
• Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

  1999cites this paper